Abstract 480P
Background
EGFR-mutant NSCLC patients(pts) have various types of co-mutation, such as TP53. Co-mutations contribute to high tumor heterogeneity in early NSCLC, potentially resulting in different clinical outcomes of resectable NSCLC. However, the impact of clinical benefit in pts with EGFR co-mutation in the ADAURA study remains unclear. Our study aimed to investigate the efficacy of the third-generation EGFR-TKI aumolertinib as adjuvant therapy for stage I-III EGFR-mutant NSCLC underwent R0 resection, and the impact of co-mutations on the clinical benefit.
Methods
We enrolled EGFR-mutant NSCLC pts who underwent radical surgery and received a daily dose of aumolertinib 110 mg. The duration of adjuvant therapy depended on the pts’pathologic stage and physical conditions. We evaluated the disease-free survival (DFS) and safety ,including the efficacy of aumolertinib in pts with co-mutation.
Results
This study retrospectively analyzed 91 cases of pathologically confirmed adenocarcinoma, EGFR positive mutation (19Del or L858R), and stage I-III NSCLC pts from August 2021 to August 2023. At the data cut-off, all pts have no symptoms of tumor recurrence. 62 pts (68.1%) have been followed up for ≥ 6 months, 27 pts (29.7%) have been followed up for ≥ 12 months. The 1-year DFS rate is 100%.
Among them, 35 pts had EGFR co-mutation and 48.5% was with TP53 co-mutation. Median age was 59 years and 74.3% were female. 17 pts (48.6%) have been followed up for ≥ 6 months, 7 pts (20%) have been followed up for ≥ 12 months. At 12 months, 100% pts were alive and disease-free, consistent with the overall population. There was no difference in postoperative recurrence between the co-mutation and the overall population currently. No grade≥3 adverse events occurred. The common adverse events were mild rash and diarrhea. No pts withdrew from therapy due to adverse drug reactions.
Conclusions
This study demonstrated the significant efficacy of aumolertinib as adjuvant therapy for completely resected stage I-III EGFR-mutated NSCLC, and reported the consistent efficacy of aumolertinib in pts with co-mutation for the first time. Our study is still ongoing to expand the cohort of pts with co-mutation and extend the follow-up period to determine longer-term outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract